Subject
Neurology (clinical),General Medicine,Pediatrics, Perinatology and Child Health
Reference36 articles.
1. Childhood spinal muscular atrophy: controversies and challenges;Mercuri;Lancet Neurol.,2012
2. Nusinersen versus sham control in infantile-onset spinal muscular atrophy;Finkel;N. Engl. J. Med.,2017
3. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial;Mercuri;Lancet Neurol.,2021
4. Risdiplam in type 1 spinal muscular atrophy;Baranello;N. Engl. J. Med.,2021
5. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data;Erdos;Eur. J. Paediatr. Neurol.,2022
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献